First study to confirm the benefit of anti-angiogenic therapy in patients with breast cancer

Results from the first and only interim analysis of an important trial assessing the potential of Herceptin (trastuzumab) to improve disease-free survival (DFS) in HER-2 positive breast cancer patients after adjuvant chemotherapy, have shown that Herceptin affords a significant survival advantage.

Continue to First study to confirm the benefit of anti-angiogenic therapy in patients with breast cancer on News-Medical News Feed.

Medical Buzz delivers the most recent headlines from the medical world. Diseases, cures, accidents, medicin. Click below for more headlines ...
Medical buzz